Overview

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pramipexole
Pregabalin